Activation or reactivation of ache
Disclosed herein is an in vitro or in vivo method of activating or reversing inactivation of acetylcholinesterase (AChE) or butyrylcholinesterase (BuchE) using compounds of the present disclosure. Also disclosed is a method of treating a subject exposed to a nerve agent using such compounds. Also disclosed is a method of treating organophosphate poisoning in a subject using such compounds. Also disclosed is a method of modulating neuronal signaling and transmission in a subject using such compounds.
1. A method of activating or reactivating an acetylcholinesterase (AChE) comprising:
contacting, in vitro or in vivo, non-activated or inactivated AChE and
a compound of Formula (II):
or a pharmaceutically acceptable salt, including all tautomers and stereoisomers, thereof wherein,
R 3 represents hydrogen;
R 4 represents hydrogen or chloro; and
R 5 represents hydrogen;
wherein the dashed line (- - - - - -) represents a bond to Formula (II).
2. The method of claim 1 , wherein the compound is
3. The method of claim 1 , wherein the compound further comprises a pharmaceutically acceptable carrier or excipient.
4. A method of activating or reactivating an acetylcholinesterase (AChE) comprising:
contacting, in vitro or in vivo, non-activated or inactivated AChE and
a compound of Formula (I):
or a pharmaceutically acceptable salt, including all tautomers and stereoisomers, thereof wherein,
R 1 represents hydrogen;
and
R 2 =hydrogen; or
wherein the dashed line (- - - - - -) represents a bond to Formula (I) and the dashed and solid line (- - - - -) of Formula (I) represents a double bond if R 1 or R 2 is hydrogen and represents a single bond if R 1 and R 2 are not hydrogen.
5. The method of claim 1 , wherein the reactivating comprises reversing inactivation of an acetylcholinesterase.
6. The method of claim 4 , wherein the reactivating comprises reversing inactivation of an acetylcholinesterase.
7. The method of claim 4 , wherein the compound is
8. The method of claim 4 , wherein the compound further comprises a pharmaceutically acceptable carrier or excipient.